After a 121.1% return over the past year, Centene's share price has moved sharply higher, while its valuation checks still suggest the stock leans cheap rather than expensive.

• Centene has delivered a 121.1% return over the last 12 months, which puts extra focus on whether the recent share price strength is already pricing in key expectations.
• The planned CFO handover to Chris Neczypor after Drew Asher retires may support confidence in financial stewardship, although any bumps in the leadership transition could affect how investors assess execution risk.
• On Simply Wall St's broader valuation checks, Centene screens as undervalued in 5 of 6 areas, which leans toward the stock being priced below what many fundamentals might justify.

The issue now is whether Centene's strong share price performance already reflects the improvement implied by those valuation checks, or if the stock still offers room based on current fundamentals.

Is Centene a Bargain on Sales?

P/S is often a useful check for health insurers like Centene because revenue is a cleaner starting point than accounting earnings that can swing around on claims and reserves.

Centene trades on a P/S of 0.2x, which is well below the Healthcare industry average of about 1.5x and also below the peer group average of about 1.9x. The tailored fair P/S ratio for Centene, which factors in its size, margins and risk profile, is 0.9x. That is materially higher than where the stock currently trades on sales.

Despite the recent CFO transition news keeping attention on execution, Centene still changes hands at a P/S multiple that indicates a notable discount relative to what this framework suggests for the business.

On the P/S multiple, Centene stock appears undervalued relative to both its tailored fair ratio and sector benchmarks.

The Centene Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Centene pick up where this valuation puzzle leaves off, by spelling out what paths for Centene's growth, margins and earnings would need to play out for the stock to be worth materially more or less than today's price, and they sit on the Community page. Rather than relying on a single multiple or model output, each narrative lays out its own assumptions so you can refer back to them as actual results are reported.

Community views on Centene are sharply split, with one side focused on margin recovery potential and the other on policy and contract risk.

Bull case: 19% undervalued

"Ongoing digital transformation and AI-driven payment integrity initiatives are set to deliver structural cost reductions and superior medical loss ratio management…"

Bear case: 15% overvalued

"Rising government scrutiny over managed care costs and ongoing legislative focus on pricing transparency are set to intensify regulatory pressure on Centene…"

Do you think there's more to the story for Centene? Head over to our Community to see what others are saying!

The Bottom Line

Centene still screens as undervalued on market multiples, especially on sales, which suggests the recent share price strength has not fully closed the discount implied by broader valuation checks. For investors, the key question is whether the current pricing reflects a genuine opportunity or simply a cushion against the policy and contract risks raised in the bear case. The crux from here is whether Centene can deliver on the margin and cost execution that more optimistic views expect without unexpected setbacks during the leadership transition.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.